Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

Abstract Background Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with meta...